A clinical study of the efficacy of paclitaxel and bevacizumab as first-line therapy for HER2-negative breast cancer

Summary. The results of treatment of patients with bevacizumab and paclitaxel as first-line therapy for HER2-negative metastatic breast cancer are presented. The median overall survival was 12,3 months (4,6–44,8 months), progression-free survival was 8,1 months (2,3–33,2 months). The findings of this study confirmed the high efficacy and acceptable toxicity of bevacizumab and paclitaxel as the first-line regimen of metastatic breast cancer.